Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Demanding NWBO get off the OTC quickly is pretty much begging for an R/S.
We should be exhorting them at the ASM to stop cowering in the corner and hiding our light under a bushel and start relearning media relations which they forgot circa 2015.
Milestones fail to matter on the SP front there is next to no media or investor relations by NWBO and so few learn of the milestones.
If we fix the longstanding communication issue then with submission and definitely with approval the SO issue goes away with no R/S needed.
I do think that we will pick up more momentum as some investors like to search for companies with pending approval decisions to play the binary event and NWBO will start appearing on those lists. These investors are gambling but have the chance to cut ahead in line and avoid all the years of opportunity cost dilution and stress that true believers endure. This creates buying pressure.
$1 even with MHRA approval is probably too pessimistic on your part.
Word of mouth can now become a factor again. This will not manifest overnight but submission is a slow burn game changer on the sentiment and SP front. Hence why I was frustrated it kept getting pushed back.
We’ll see. Hopefully you are right and things have just been poorly communicated to shareholders.
Regardless, today at least, after 3+ years we finally got an application submitted to a regulator and that makes it a good day.
No matter what, with today’s news 2023 should be the Last ‘Lost Year’ NWBO shareholders ever have.
It’s all but guaranteed and any NWBO shareholder knows to be very cautious when talking about guarantees.
With a pending decision by regulators now here the rules should start to change and greater interest should start to focus on NWBO from people who have never been involved in this drama before.
It all depends upon whether NWBO management shares the belief in corruption at the FDA that their shareholders hold.
If NWBO thinks FDA is corrupt they are going to wait until MHRA has had the application a long time.
This will mean that any MHRA approval will be public knowledge long before FDA can weigh in.
The political environment an MHRA approval will create should offset any effects of perceived corruption at FDA.
Given how demonstrably bad they have been at estimating time frames, NWBO might decide to just wait for MHRA approval before submitting to FDA to eliminate any chance for shenanigans.
Has NWBO said this or is this your opinion?
Furthermore, even if you are right then Manufacturing, Manufacturing, Manufacturing requires a Checkbook, a Checkbook a Checkbook.
That means that Linda Powers’ fatuous boast so many years ago that “All Big Pharma brings to the table is a checkbook” has aged especially poorly.
This leaves aside the fact that NWBO investors got diluted and already pumped money into Manufacturing, Manufacturing, Manufacturing at Cognate, only for it to (completely legally of course) get sold out from under us.
What is NWBO shareholder percentage of ownership of Advent again? What customers did Cognate have besides NWBO and what customers does Advent have besides us? Does Advent do whatever NWBO says like some management supporters claim or is it us independent as some management supporters have more recently said the government says it must be?
That is true if NWBO repeats the pattern of letting down those who believe in them the most and this time is no different.
For my part I’ll be happy to keep handling any posts (except the single farewell post) by losers on either side until I am pressured by those above who unlike me, get paid to deal with this stuff.
So those who want to welsh will have that little recycle icon to remind folks that they lost and are still hanging around.
You have to understand:
Flipper is looking to escape this purgatory.
Either NWBO proves it is worth following or it doesn’t. If it doesn’t he can still hold his shares but effectively divorce NWBO and see if they ever pay alimony but in the meantime will be free.
I a felt the same when I gave management a chance to shut me up on criticism not with intimidation but through deeds and I set a damned low standard and even extended the deadline. Nope, not even then.
I voted for the share increase and compensation at the last ASM because they did deliver on TLD and the article even if they signally failed to really benefit shareholders and especially long time shareholders as folks had reasonably anticipated would happen after those major milestones.
I was trying to reward at least the delivery of those milestones (even if we received a scratch and dent product) and thereby encourage better behavior by management.
Instead 2023 is effectively a waste (no matter whether we get submission with no time left in the year for the regulator to do anything or not).
Instead folks deliberately misconstrued my vote and those of others who held their noses to vote yes as uncritical support for everything management had done.
So this year, short of management bringing in serious non-dilutive revenue before the ASM I am voting no for the ASM that covers 2023, based on their poor performance.
If they want my vote for the ASM covering 2024 they can get an MHRA and FDA approval and achieve uplisting with no R/S.
I tried helping out NWBO management with an extended deadline before and got burned by them last time.
Even so in the spirit of the Season I will remind everyone that technically the Christmas season extends all the way into early January and the Epiphany.
You’re not asking too much and hopefully you won’t have to ask the Easter Bunny.
Thank you. This will aid in enforcement to either side later.
I can’t believe we finally agree on something. I don’t know who they are in real life and I don’t care. I just know that what they said about me was false and I have only posted under this handle here and I haven’t posted on Yahoo in quite a few years. So if they got that wrong they are probably wrong about a lot more.
While we normally disagree on the science and I don’t like shorts any more than I like shills or traders, I’d be curious to see if anyone can refute this with evidence instead of just attacking you.
If they attack you without addressing your point it indicates you are probably right because this is not an issue that has been endlessly discussed as the trial data has so there is no excuse to just say ‘asked and answered’ or use the ‘I have no proof (I’m not here to educate you)’ line.
Look I don’t need help from folks like yourself on the short side to discuss this issue. It’s a matter for us long shareholders to discuss as it’s our money.
I doubt you are a shareholder too. A real shareholders would never be hostile to legitimate questions like I ask. I don’t think the 10Q provided a credible explanation for why we have no meaningful Specials revenue or it would have been trumpeted by management supporters repeatedly.
Where is the Specials revenue?
Shareholders have a right to know especially in light of the previous (perfectly legal) but less than advantageous Cognate deal.
If there is no revenue in late 2023 why not?
This concerns one of our few near term sources of revenue when almost every dollar spent comes out of our equity ‘right before the end.’
Only a (hopefully unpaid and uncoordinated) management denies our moral if not legal right to know (laws are written by lobbyists so we have few legal rights of course).
Do you really think NWBO would pass along that money to us?
Even if we got MHRA submission in tomorrow except for who wins the get here on IHUB, it doesn’t change the fact that 2023 is another lost years
Unlike if we had actually submitted in October 2023, is too little time left this year for anything to happen at MHRA and the government officials there are sure to be in Holiday Mode until at least after New Year’s Day.
It’s December 2023.
The same argument was made this time in 2022 and 2021 and 2020.and so on.
It’s time for NWBO to unlock some of that $100 billion value as measured by the SP.
Now, not in ‘another six months’ or in 2025.
The bet is an excuse to escape this quagmire.
Good idea. If you visit Bethesda and do some caroling outside the door for figgy pudding and submission to MHRA maybe you’ll get it. Have fun and dress warmly!
Your logic is sound but was repeated in 2022 by those who said it isn’t 2020 and so on. That’s an evil aspect of the cycle. This time is always different, until it’s not.
Out of hardheadedness I am not selling any of my many NWBO shares and will buy over time to at least offset dilution and lowly lower my cost basis.
I intend to have every share when news that actually matters for shareholders in the here and now finally hits.
Hopefully NWBO will at least not stiff us on the submission announcement and you’ll be with us in the New Year.
If not, you did not really lose your bet, as you found a good pretext to make your escape from my poor writing.
Maybe the next time there’s a bet I’ll jump in on it to get out of here too and having no other profiles that’ll be it.
This was the single most important news event in NWBO history and yet the company seemed unwilling to put a strategy in place to amplify the impact and finally get the SP to a new level.
It is easy to forget how impactful everyone expected TLD to be for all of us.
NWBO management rolled out (or rather had others roll out) the news on May 10th so ineffectually that I have seen some of their supporters here reduced to suggesting that the announcement of TLD was meant to fail as part of an elaborate trap to prove stock manipulation.
NWBO also set the expectation that the journal article would be there close in time to bolster TLD and when that didn’t happen things were scarcely improved. Remember TLD was ostensibly delayed for the JA under the vaunted ‘Plan’ from October 5th we heard about over and over again whenever the long wait on TLD was questioned.
As to Feuerstein:
Didn’t Adam Feuerstein exploit the fact that clinicaltrials.gov still officially listed overall survival as the primary endpoint?
It gave him the ability to plausibly wave around official information to say that at least as far as the trial in the US was concerned we failed.
Weren’t we told by management supporters that the company was being somehow strategic in not updating the clinicaltrials.gov website?
A lot of us called early for the company to at least make sure the official government information on both sides of the Atlantic for the endpoints was right .
I doubt they are insiders but I do suggest there are some commentators, who if nothing else, through sheer affinity of belief with management’s side seem to mirror the ‘company line’ closely that if they are characterizing the future in a certain way it can be telling.
So if they are managing expectations and suggesting that the impact of submission will be blunted and generating a narrative to explain that in advance, then this, unfortunately, could happen.
The ‘why’ is impossible to know absent bring given the gift of telepathy or (if they committed their thoughts to writing), a subpoena.
I can only tell you that they’ve been dragging things out for years by going on side quests like the JAMA article (which not only failed to protect TLD from media attacks but did not even secure a scientific consensus in favor of DCVax-L).
Every step has substeps that appear and each take forever. Even their recent big ‘makeup’ expectation of telling us when they handed off to the publisher fell flat because they only told us of a partial handoff, and not the complete handoff we expected. Go figure.
The nicest explanation (from their own partisans no less) is that they are dragging things out for manufacturing to get in place. But even this logic would require us to believe NWBO management is being less than forthright and not admitting the fact the existing manufacturing process is thereby deemed inadequate for profitable commercialization.
Never mind that years ago I remember management saying something to the effect that unlike DNDN they had manufacturing understood. So the current manufacturing process being inadequate was not the bill of goods many of us were sold.
Looks like that ‘we’re better than DNDN’ was more aspiration than not reality and is contingent on us getting bargain basement tech ready for prime time at the last minute. Which with every complex task NWBO undertakes is apparently going as well and as quickly as expected.
So hopefully it’s not manufacturing as management supporters say and just their natural perfectionism or tendency to procrastinate because otherwise things might not go so well.
I would love to be wrong and if I am it is probably due to some of the information that we are (quite legally I am sure) not being told about what is happening behind the scenes.
I would pay heed when folks closely aligned with NWBO management are already trying to manage shareholder expectations about the impact of submission to MHRA and trying, in advance, to blame everything but the piss poor public and investor relations of this firm for what they are telegraphing will be an underwhelming market response.
They are signaling that NWBO management will pull another May 10th and release important news in a fashion that is nowhere near best calculated to maximize the positive impact on the SP (long gone of course is the Big Talk that NWBO was saving up all their news to release in a continuous unstoppable barrage).
I agree with you that NWBO should appear at conferences but those closest to them here are signaling that at least until approval and probably (FDA approval and not MHRA approval) the same communication ‘strategy’ will be in effect.
Sadly it’s not original at all because this cycle has repeated itself a few times even if the exact catalyst we think is going to permanently and dramatically change everything for the better (for real this time) is different.
You can go back and find similar predictions and similar rejoinders from prior cycles.
As your post shows, ‘soon’ is a useless term for actual discussion of when things are likely to happen because shareholders are coming from such different reference points.
Even ‘a few’ has lost a lot of meaning.
From the outset it is better to say in less than 4 months or (even better)between 90 and 120 calendar days etc.
Then people don’t have to waste time posting to argue over what soon means and refocuses the discussion on the company.
Poor Man assuming you follow through with your law suit(s), this should give you some idea of what the jury is likely to award:
https://www.latimes.com/archives/la-xpm-1986-07-30-sp-18643-story.html
Unfortunately, the laws are rarely enforced, as we all know, and when they are the fines are just a haircut off of the top.
The law should be enforced against market makers, I agree.
However those shareholders who wanted TLD to be released within one year of data lock (as the law appeared to require) know that enforcement is an issue and regulatory inaction or effective rewriting of the law to subvert legislative intent is a problem.
The sauce that’s good for the goose is good for the gander and if one accepted the premise that it was okay to ignore supposedly ‘toothless laws’ then back one must accept it now. Who is benefitting or being criticized should not effect one’s stance.
I did not accept that premise before so I do not accept it now. Enforcement the law on all parties.
Look nothing stops the losers from heading there. Still helps out here, whoever wins.
Flipper has clearly gotten where all shareholders will get unless things change - if NWBO lets him down one more time he’ll stop defending them and force them to do their own talking.